Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection

N Frumento, A Sinnis-Bourozikas, HT Paul, G Stavrakis… - Immunity, 2024 - cell.com
Individuals who clear primary hepatitis C virus (HCV) infections clear subsequent
reinfections more than 80% of the time, but the mechanisms are poorly defined. Here, we …

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis

H Zhang, AA Quadeer, MR McKay - Nature Communications, 2023 - nature.com
Direct-acting antiviral agents (DAAs) provide efficacious therapeutic treatments for chronic
Hepatitis C virus (HCV) infection. However, emergence of drug resistance mutations (DRMs) …

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

DA Smith, D Bradshaw, JL Mbisa… - Journal of Viral …, 2021 - Wiley Online Library
Sustained viral response (SVR) rates for direct‐acting antiviral (DAA) therapy for hepatitis C
virus (HCV) infection routinely exceed 95%. However, a small number of patients require …

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus

MA Ansari, E Aranday-Cortes, CLC Ip, A da Silva Filipe… - Elife, 2019 - elifesciences.org
Hepatitis C virus (HCV) is a highly variable pathogen that frequently establishes chronic
infection. This genetic variability is affected by the adaptive immune response but the …

Emergence of compensatory mutations reveals the importance of electrostatic interactions between HIV-1 integrase and genomic RNA

C Shema Mugisha, T Dinh, A Kumar, K Tenneti… - MBio, 2022 - Am Soc Microbiol
ABSTRACT HIV-1 integrase (IN) has a noncatalytic function in virion maturation through its
binding to the viral RNA genome (gRNA). Class II IN substitutions inhibit IN-gRNA binding …

Technical validation of a hepatitis C virus whole genome sequencing assay for detection of genotype and antiviral resistance in the clinical pathway

CF Manso, DF Bibby, K Lythgow, H Mohamed… - Frontiers in …, 2020 - frontiersin.org
Choice of direct acting antiviral (DAA) therapy for Hepatitis C Virus (HCV) in the United
Kingdom and similar settings usually requires knowledge of the genotype and, in some …

HCV E1 influences the fitness landscape of E2 and may enhance escape from E2-specific antibodies

H Zhang, RA Bull, AA Quadeer, MR McKay - Virus Evolution, 2023 - academic.oup.com
Abstract The Hepatitis C virus (HCV) envelope glycoprotein E1 forms a non-covalent
heterodimer with E2, the main target of neutralizing antibodies. How E1–E2 interactions …

Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

LW Madsen, PB Christensen, U Fahnøe… - Liver …, 2021 - Wiley Online Library
Abstract Background & Aims Shortening the treatment duration for chronic hepatitis C may
increase feasibility and reduce the cost of cure. The aims of this study were to compare 4 …

A comparison of bioinformatics pipelines for enrichment Illumina next generation sequencing Systems in Detecting SARS-CoV-2 virus strains

Afiahayati, S Bernard, Gunadi, H Wibawa, MS Hakim… - Genes, 2022 - mdpi.com
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a newly emerging
virus well known as the major cause of the worldwide pandemic due to Coronavirus Disease …

Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals

JL Mbisa, Z Lapp, DF Bibby, LT Phillips… - The Journal of …, 2024 - academic.oup.com
Abstract Background Hepatitis C virus (HCV) has high genetic diversity and is classified into
8 genotypes and> 90 subtypes, with some endemic to specific world regions. This could …